Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CO3.Al.Na.2HO |
| Molecular Weight | 143.9949 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[Na+].[Al+3].[O-]C([O-])=O
InChI
InChIKey=SEIGJEJVIMIXIU-UHFFFAOYSA-J
InChI=1S/CH2O3.Al.Na.2H2O/c2-1(3)4;;;;/h(H2,2,3,4);;;2*1H2/q;+3;+1;;/p-4
Potash (Dihydroxyaluminum Sodium Carbonate), a component of
Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.drugbank.ca/drugs/DB09460 |
|||
Target ID: CHEMBL205 Sources: https://www.drugbank.ca/drugs/DB09460 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Kompensan Approved UseGastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate. | 1991 |
|
| Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence. | 1990-05-01 |
|
| Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate. | 1988-07 |
|
| Exchange of sodium by magnesium in aluminum hydroxycarbonate gel. | 1984-07 |
|
| Studies on antacids. V. The preparation and properties of dihydroxy aluminum sodium carbonate. | 1955-04 |
Patents
Sample Use Guides
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23163
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
C76484
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
240-536-4
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
C016386
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
539-68-4
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
SUPERSEDED | |||
|
100000079203
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
84H8Z9550J
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
m4472
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB13596MIG
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
DTXSID101340737
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
12011-77-7
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
ALTERNATIVE | |||
|
84H8Z9550J
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
16482-55-6
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY | |||
|
9793815
Created by
admin on Mon Mar 31 17:36:30 GMT 2025 , Edited by admin on Mon Mar 31 17:36:30 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD